Related references
Note: Only part of the references are listed.Geographic Shifts in Antibacterial Drug Clinical Trial Enrollment: Implications for Generalizability
Stephen M. Bart et al.
CLINICAL INFECTIOUS DISEASES (2021)
Lefamulin for Treating Community-acquired Bacterial Pneumonia in Adult Patients Aged <65 Years Reply
Thomas M. File et al.
CLINICAL INFECTIOUS DISEASES (2020)
The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States
Rodrigo Cavallazzi et al.
CHEST (2020)
Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
Thomas Lodise et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016)
Susanne Paukner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M. File et al.
CLINICAL INFECTIOUS DISEASES (2019)
Diagnosis and Treatment of Adults with Community-acquired Pneumonia An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
Joshua P. Metlay et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial
Elizabeth Alexander et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial
Douwe F. Postma et al.
BMC INFECTIOUS DISEASES (2019)
The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance
Paula Peyrani et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2019)
An update on adverse drug reactions related to -lactam antibiotics
Konstantinos Z. Vardakas et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China
Ken B. Waites et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days
Daniel G. Wootton et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon
B. Amalakuhan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Antimicrobials and QT prolongation
Jay W. Mason
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Regulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the Good
B. Spellberg et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism
Zohar Eyal et al.
SCIENTIFIC REPORTS (2016)
The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia
Carlos M. Luna et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2016)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Modified IDSA/ATS Minor Criteria for Severe Community-Acquired Pneumonia Best Predicted Mortality
Hai-yan Li et al.
MEDICINE (2015)
Etiology and Factors Contributing to the Severity and Mortality of Community-acquired Pneumonia
Takashi Ishiguro et al.
INTERNAL MEDICINE (2013)
US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions
S. Christopher Jones et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
Clinical and economic burden of community-acquired pneumonia among adults in Europe
T. Welte et al.
THORAX (2012)
Burden of Community-Acquired Pneumonia in North American Adults
Thomas M. File et al.
POSTGRADUATE MEDICINE (2010)
The Pneumonia Severity Index: A Decade after the Initial Derivation and Validation
Drahomir Aujesky et al.
CLINICAL INFECTIOUS DISEASES (2008)
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults
Lionel A. Mandell et al.
CLINICAL INFECTIOUS DISEASES (2007)
Inhibition of peptide bond formation by pleuromutilins:: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin
F Schlünzen et al.
MOLECULAR MICROBIOLOGY (2004)
What clinicians should know about the QT interval
SM Al-Khatib et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Share Paper
